Northeast Pharmaceutical Group Co., Ltd. releases the 2025 Independent Director Performance Report, focusing on related-party transactions and executive compensation

China Visit Net data Northeast Pharmaceutical Group Co., Ltd. (hereinafter referred to as “Northeast Pharmaceutical”) recently released its 2025 annual report on the work of independent directors. The report shows that during its term in 2025, the independent directors strictly complied with relevant laws, regulations, and the company’s articles of association, diligently performed their duties, and focused on several major matters of the company.

Regarding related-party transactions, the company convened board meetings in March and April 2025, respectively, to review and approve the 2025 annual estimate of ordinary related-party transactions and the adjustment proposals. Based on the adjusted estimates, the total projected amount of all types of ordinary related-party transactions between the company and its subsidiaries with related parties in 2025 is RMB 57,600 million. This proposal has been submitted to the 2024 annual general meeting of shareholders for deliberation and approval.

In terms of financial audit, the company reappointed the firm of Zhi Tong Certified Public Accountants (special general partnership) as the audit institution for the company’s 2025 financial statements and internal control. At the same time, the company timely prepared and disclosed the 2024 annual report, the 2024 internal control self-assessment report, and the 2025 first-quarter report.

In personnel and compensation, during the reporting period, the company completed the board re-election and the appointment of senior management. The company’s board of directors and shareholders’ meeting deliberated and approved the compensation plan for directors and senior management for 2024. In addition, the company also approved the proposal regarding the achievement of conditions for the release from lock-up of the second lock-up period for the reserved grant portion under the 2022 restricted stock incentive plan.

In the report, the independent directors stated that during their tenure they actively attended meetings of the board of directors, special committees, and the shareholders’ meeting, carefully deliberated on each proposal, and maintained communication with the internal audit institution and the accounting firm. They used their own professional expertise to independently and objectively express their opinions, and worked to protect the company’s overall interests and the legitimate rights and interests of all shareholders, especially minority shareholders. The report notes that the company’s management provided sufficient support and coordination for the independent directors to perform their duties.

Endless information and precise interpretation are all available in the Sina Finance app